WEB NEWS Research
LifeVantage Corporation (NASDAQ:LFVN) ($11.97; $150.2M market cap) announced Q3 2025 results:
Guidance
The Company expects FY2025 revenue between $228 million to $235 million, adjusted EBITDA of $21 million to $24 million, and adjusted EPS of $0.72 to $0.88. Full-year tax rate is expected to be 22% to 24%.
Management Commentary
“Third quarter results were strong with revenues up 21% year-over-year to $58.4 million, reflecting robust demand for our MindBody GLP-1 System™,” said Steve Fife, President and CEO of LifeVantage. “We also delivered another quarter of improving profitability including a 210 basis point improvement in gross margin and 27% increase in Adjusted EBITDA. International expansion was a key focus in the quarter with the launch of our Evolve Compensation Plan into the Philippines, Taiwan, Hong Kong and Singapore in early March followed by the launch of the MB System™, as our GLP-1 activation product is known outside of the U.S., into Japan, Australia, New Zealand, Europe, the UK, Mexico, and Thailand. At our annual Global Convention in April, the incredible intensity and engagement of our independent Consultants underscored the tremendous growth potential for LifeVantage as our addressable market continues to broaden and we leverage our unique position around Activation.”
Lifevantage engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and probiotics, weight management, skin and hair care, bath and body, and targeted relief products.
Research
Lifevantage Corporation (NASDAQ:LFVN) ($16.82; $216.5 M market cap) announced the launch of the Evolve Compensation plan into the Philippines, Taiwan, Hong Kong and Singapore.
“When we launched the LV360 and the Evolve Compensation Plan two years ago, we did so with a clear vision of where the direct sales industry was headed,” said Steve Fife, President and CEO of LifeVantage. “That transformation has proven invaluable for our independent Consultants, equipping them for the world we live in today. As we enter this next phase, we’re proud to bring this transformation to more international markets and empower Consultants with the tools to help their businesses thrive.”
Lifevantage engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and probiotics, weight management, skin and hair care, bath and body, and targeted relief products.
Research
Lifevantage Corporation (NASDAQ:LFVN) ($22.74; $284.8 M market cap) (currently marked down ~20% pre market) announced Q2 2025 results:
Sales of $67.8 million vs $51.6 million in the prior year, in line with analyst estimates of $67.3 million
Non-GAAP EPS of $0.22 vs $0.10 in the prior year and well ahead of analyst EPS estimate of $0.13
“Second quarter results were outstanding with year-over-year revenue growth exceeding 31% to a record $67.8 million, driven by tremendous demand for the MindBody GLP-1 System™ we introduced into the U.S. market in October,” said Steve Fife, President and CEO of LifeVantage. “We also continued to deliver strong profitability metrics and growth in Active Accounts, which was equally impressive, up 25% sequentially in the Americas, as the number of enrollments surged to the highest level in five years. Across our business we’re seeing incredible momentum and the entire LifeVantage community of independent Consultants and customers is highly engaged. MindBody significantly expands our addressable market with a unique weight management solution while also creating synergistic growth opportunities across our other core product lines. We are just at the beginning of this exciting journey and with a strong balance sheet and leverageable platform, are well positioned for long-term success.”
Fiscal Year 2025 Guidance
“The Company expects revenue in the range of $235 million to $245 million in fiscal year 2025, up from the original guidance of $200 million to $210 million, adjusted EBITDA of $21 million to $24 million, up from $18 million to $21 million, and adjusted earnings per share in the range of $0.72 to $0.88, up from $0.70 to $0.80.”
Guidance is in line with analyst estimates for 2025—$238.4 million in sales and $0.76 in EPS.
Shares are extremely weak in the pre-market. Having said that, the stock did have a huge run, so it is possible investors were looking for a stronger increase in guidance.
Lifevantage engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and probiotics, weight management, skin and hair care, bath and body, and targeted relief products.
Research
Lifevantage Corporation (NASDAQ:LFVN) ($8.53; $106.4 M market cap) announced positive in vitro results for its new GLP-1 system. The Company is finally getting more descriptive about some of the details surrounding its new GLP 1 weight loss therapy expected to be launched on October 15, 2024.
“This in vitro study confirms the harmonious nature of our innovative two-product system that approaches GLP-1 activation through both direct activation of L-cells and optimizing the gut microbiome in the colon to enhance GLP-1 production,” said Lisa Barnes, Vice President of Research and Development at LifeVantage. “With the development of this system, LifeVantage continues to leverage our unique Activation approach, using the latest science and naturally-derived ingredients to help your body make what it needs to be healthy.”
Lifevantage engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and probiotics, weight management, skin and hair care, bath and body, and targeted relief products.
Research
Lifevantage Corporation (NASDAQ:LFVN) ($8.60; $109.2 M market cap) concludes Park City retreat with an exclusive preview of its innovative weight management solution.
“Attendees also enjoyed an exclusive preview of LifeVantage’s innovative weight management products, designed to activate natural production of the GLP-1 hormone, reduce food noise, and support healthy weight goals.
Consultants who earned the trip were given the unique opportunity to be on the new weight management system ahead of its official launch in October. The preview encouraged collaboration, with participants brainstorming strategies to build excitement over the next six weeks, leveraging authentic stories and results to drive broader engagement within the LifeVantage community.”
On July 26, 2024 we issued a special buy on pullback alert for LFVN based on its expected launch of GLP-1 nutraceutical treatment for weight loss. See our special alert note here .
Research
Lifevantage Corporation (NASDAQ:LFVN) ($6.79; $86.3 M market cap) will be participating in the Water Tower Research Fireside chat series on Thursday, December 14th at 11:00 AM EST.
This event is open access for all investors to participate. Topics may include:
LifeVantage’s strategy of activating financial, social, and community wellness through its proprietary product portfolio and its connected network of independent consultants.
The recent implementation of its LV360 initiatives, including the new Evolve compensation plan for its consultants.
New product activity, including the widely successful Liquid Collagen product.
The Company’s improving profitability, strong balance sheet, significant free cash flow and capital allocation strategy that drives shareholder value through dividends and share repurchases.
The link to register for the event can be found here .
We added LFVN to our Buy on Pullback Model Portfolio in mid November when the stock was trading at $5.05.
